PFE Stock Analysis: Pfizer | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 149.331m USD | 12M Return: 14% | US7170811035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.02B
EPS Trend: 61.5%
Qual. Beats: 0
Rev. Trend: 26.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pfizer Inc. is a New York-based global biopharmaceutical company founded in 1849, operating in three segments: Biopharma, PC1, and Pfizer Ignite. The pharmaceutical sector is characterized by long R&D cycles, heavy regulatory oversight, and reliance on patent-protected products, which typically drive a high-cost, high-margin business model.
The company markets a diversified portfolio spanning internal medicine, vaccines, inflammation and immunology, rare diseases, oncology, biosimilars, and sterile injectables. Major brands include Eliquis, Prevnar, Paxlovid, Xeljanz, Vyndaqel, Ibrance, and Xtandi. Pharma companies like Pfizer typically generate revenue from a mix of blockbuster patented therapies and, increasingly, lower-margin biosimilars as patents expire.
Pfizer maintains collaboration agreements with Bristol-Myers Squibb, Astellas Pharma, Merck KGaA, and BioNTech, as well as a strategic AI partnership with Boltz, PBC. Such alliances are common in the biopharma industry, where co-development and licensing agreements help share R&D risk and accelerate pipeline expansion across global markets.
- Paxlovid and Comirnaty revenue decline steepens post-pandemic
- Eliquis patent expiry threatens multi-billion dollar revenue base
- Seagen acquisition integration drives oncology segment growth
| Net Income: 4.33b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 13.68% < 20% (prev 9.36%; Δ 4.31% < -1%) |
| CFO/TA 0.07 > 3% & CFO 13.4b > Net Income 4.33b |
| Net Debt (51.5b) to EBITDA (12.6b): 4.08 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.70b) vs 12m ago -0.12% < -2% |
| Gross Margin: 71.32% > 18% (prev 67.34%; Δ 3.98% > 0.5%) |
| Asset Turnover: 31.28% > 50% (prev 30.97%; Δ 0.31% > 0%) |
| Interest Coverage Ratio: 2.56 > 6 (EBIT TTM 6.91b / Interest Expense TTM 2.70b) |
| A: 0.04 (Total Current Assets 41.4b - Total Current Liabilities 32.6b) / Total Assets 201b |
| B: 0.56 (Retained Earnings 112b / Total Assets 201b) |
| C: 0.03 (EBIT TTM 6.91b / Avg Total Assets 204b) |
| D: 0.74 (Book Value of Equity 85.2b / Total Liabilities 116b) |
| Altman-Z'' = 3.10 = A |
| DSRI: 0.78 (Receivables 12.5b/16.1b, Revenue 63.7b/63.8b) |
| GMI: 0.94 (GM 67.34% / 71.32%) |
| AQI: 1.00 (AQ_t 0.70 / AQ_t-1 0.70) |
| SGI: 1.00 (Revenue 63.7b / 63.8b) |
| TATA: -0.05 (NI 4.33b - CFO 13.4b) / TA 201b) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of August 14, 2026, the stock is trading at USD 26.80 with a total of 29,882,548 shares traded. Over the past week, the price has changed by +2.29%, over one month by +11.39%, over three months by +5.04% and over the past year by +13.99%.
Current recommended Stop Loss: 26.00 (which is 3% or 1.4 ATR below the current price).
Pfizer has received a consensus analysts rating of 3.56. Therefore, it is recommended to hold PFE.
- StrongBuy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 28.8 | 7.4% |
P/E Trailing = 34.026
P/E Forward = 8.673
P/S = 2.3444
P/B = 1.7001
P/EG = 2.9905
Revenue TTM = 63.7b USD
EBIT TTM = 6.91b USD
EBITDA TTM = 12.6b USD
Long Term Debt = 60.5b USD (from longTermDebt, last quarter)
Short Term Debt = 2.70b USD (from shortTermDebt, last quarter)
Debt = 63.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 51.5b USD (calculated: Debt 63.2b - CCE 11.7b)
Enterprise Value = 201b USD (149b + Debt 63.2b - CCE 11.7b)
Interest Coverage Ratio = 2.56 (Ebit TTM 6.91b / Interest Expense TTM 2.70b)
EV/FCF = 18.28x (Enterprise Value 201b / FCF TTM 11.0b)
FCF Yield = 5.47% (FCF TTM 11.0b / Enterprise Value 201b)
FCF Margin = 17.25% (FCF TTM 11.0b / Revenue TTM 63.7b)
Net Margin = 6.81% (Net Income TTM 4.33b / Revenue TTM 63.7b)
Gross Margin = 71.32% ((Revenue TTM 63.7b - Cost of Revenue TTM 18.3b) / Revenue TTM)
Gross Margin QoQ = 72.78% (prev 67.26%)
Tobins Q-Ratio = 1.00 (Enterprise Value 201b / Total Assets 201b)
Interest Expense / Debt = 4.27% (Interest Expense 2.70b / Debt 63.2b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 5.46b (EBIT 6.91b * (1 - 21.00%))
Current Ratio = 1.27 (Total Current Assets 41.4b / Total Current Liabilities 32.6b)
Debt / Equity = 0.74 (Debt 63.2b / totalStockholderEquity, last quarter 85.2b)
Debt / EBITDA = 4.08 (Net Debt 51.5b / EBITDA 12.6b)
Debt / FCF = 4.69 (Net Debt 51.5b / FCF TTM 11.0b)
Total Stockholder Equity = 88.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.13% (Net Income 4.33b / Total Assets 201b)
RoE = 4.89% (Net Income TTM 4.33b / Total Stockholder Equity 88.6b)
RoCE = 4.63% (EBIT 6.91b / Capital Employed (Equity 88.6b + L.T.Debt 60.5b))
RoIC = 3.25% (NOPAT 5.46b / Invested Capital 168b)
WACC = 6.18% (E(149b)/V(213b) * Re(7.37%) + D(63.2b)/V(213b) * Rd(4.27%) * (1-Tc(0.21)))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 29.76 | Cagr: 0.02%
[DCF] Terminal Value 73.68% ; FCFF base≈11.6b ; Y1≈10.5b ; Y5≈9.02b
[DCF] Fair Price = 16.17 (EV 144b - Net Debt 51.5b = Equity 92.2b / Shares 5.70b; r=8.35% [WACC [floored]]; 5y FCF grow -11.67% → 2.50% )
EPS Correlation: 61.47 | EPS CAGR: 25.46% | SUE: 0.71 | # QB: 0
Revenue Correlation: 26.30 | Revenue CAGR: 1.73% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.80 | Chg30d=-5.21% | Revisions=-36% | Analysts=18
EPS current Year (2026-12-31): EPS=2.95 | Chg30d=-0.31% | Revisions=-7% | GrowthEPS=-8.4% | GrowthRev=-1.4%
EPS next Year (2027-12-31): EPS=2.84 | Chg30d=+0.35% | Revisions=+21% | GrowthEPS=-3.8% | GrowthRev=-3.8%
[Analyst] Revisions Ratio: -6% (up=14, down=16)